//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы


Thompson I.M. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350:2239. https://www.ncbi.nlm.nih.gov/pubmed/15163773.

Arlen P.M. et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008;179:2181. https://www.ncbi.nlm.nih.gov/pubmed/18423743.

Catalona W.J. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542. https://www.ncbi.nlm.nih.gov/pubmed/9605898.

Loeb S. et al. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014;6:74. https://www.ncbi.nlm.nih.gov/pubmed/24688603.

De la Calle C. et al. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men. J Urol. 2015;194:65. https://www.ncbi.nlm.nih.gov/pubmed/25636659.

Nordstrom T. et al. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol. 2015;68:139. https://www.ncbi.nlm.nih.gov/pubmed/25151013.

Eastham J.A. et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003;289:2695. https://www.ncbi.nlm.nih.gov/pubmed/12771116.

Stephan C. et al. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem. 2006;52:59. https://www.ncbi.nlm.nih.gov/pubmed/16391327.

Eggener S.E. et al. Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial. BJU Int. 2013;112:925. https://www.ncbi.nlm.nih.gov/pubmed/23890317.

Hara R. et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus

//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы


transrectal systematic 12-core biopsy. Urology. 2008;71:191. https://www.ncbi.nlm.nih.gov/pubmed/18308081. 102 PROSTATE CANCER - UPDATE MARCH 2017.

Takenaka A. et al. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis. 2008;11:134. https://www.ncbi.nlm.nih.gov/pubmed/17533394.

Donovan J. et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7:1. https://www.ncbi.nlm.nih.gov/pubmed/12709289.

Eichler K. et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:1605. https://www.ncbi.nlm.nih.gov/pubmed/16600713.

Shariat S.F. et al. Using biopsy to detect prostate cancer. Rev Urol. 2008;10:262. https://www.ncbi.nlm.nih.gov/pubmed/19145270.

Epstein J.I. et al. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006;175:820. https://www.ncbi.nlm.nih.gov/pubmed/16469560.

Merrimen J.L. et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol. 2009;182:485. https://www.ncbi.nlm.nih.gov/pubmed/19524976.

Kronz J.D. et al. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. Hum Pathol. 2001;32:389. https://www.ncbi.nlm.nih.gov/pubmed/11331955.

Guo C.C. et al. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol. 2006;19:1528. https://www.ncbi.nlm.nih.gov/pubmed/16980940.

Zigeuner R. et al. Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology. 2003;62:883. https://www.ncbi.nlm.nih.gov/pubmed/14624913.